VBIVQ — VBI Vaccines Share News
0.000.00%
Last trade - 00:00- $0.01m
- $36.16m
- $8.68m
U.S. RESEARCH ROUNDUP-Freeport-Mcmoran, Harley-Davidson, Varonis Systems
VBI Vaccines Inc reports results for the quarter ended in December - Earnings Summary
Brief: Vbi Vaccines Reports Full Year 2022 Financial Results
VBI Vaccines Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: VBI Vaccines Announces Presentation Of Interim Phase 2 Data Of VBI-2601 (BRII-179) & BRII-835
Brief: Nasdaq Grants VBI Vaccines That Co Has Until June 26, 2023, To Regain Compliance
Brief: VBI Vaccines Announces Health Canada Approval For Prehevbrio
Brief: CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal
Brief: Vbi Vaccines Presents Additional Phase 1/2A Data From Vbi-1901 In Recurrent GBM At The 2022 Society For Neuro-Oncology (Sno) Annual Meeting
Brief: VBI Vaccines Presents Additional Phase 1/2A Data From VBI-1901 In Recurrent GBM At The 2022 Society For Neuro-Oncology Annual Meeting
VBI Vaccines Inc reports results for the quarter ended in September - Earnings Summary
VBI Vaccines Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Ferring International Center And Scivac, Subsidiary Of VBI Vaccines Inc, Amended And Restated License Agreement
Brief: Vbi Vaccines And Agenus Announce Collaboration To Evaluate Vbi-1901 In Combination With Anti-Pd-1 Balstilimab In A Phase 2 Study In Primary Glioblastoma Patients
Brief: Vbi Vaccines And Agenus Announce Collaboration To Evaluate Vbi-1901 In Combination With Anti-Pd-1 Balstilimab In A Phase 2 Study In Primary Glioblastoma Patients
Brief: VBI Vaccines Announces Initiation Of Phase 1 Study Of Multivalent Coronavirus Vaccine Candidate, VBI-2901
Brief: Vbi Vaccines Inc - On September 14, Entered Second Amendment To Loan Agreement
Brief: VBI Vaccines Secures $100 Million Debt Facility From K2 Healthventures
French and Benelux stocks-Factors to watch